

Material Safety Data Sheet

MSDS Preparation Date: 28/09/2011
MSDS Revision Date: 28/09/2014

Axitinib

Cat. No: 4350

Batch No: 1

N-Methyl-[[3[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide

1. COMPOSITION/INFORMATION ON INGREDIENTS

For batch specific information, please see Product Information sheet.

2. PHYSICAL AND CHEMICAL PROPERTIES

For batch specific information, please see Product Information sheet.

3. HANDLING AND STORAGE

Use in a chemical fume hood, with air supplied by an independent system. Avoid inhalation, contact with eyes, skin and clothing. Avoid prolonged or repeated exposure.

Material should be stored in a tightly sealed container under the storage condition stated on the Product Information sheet and on the vial label.

4. STABILITY AND REACTIVITY

Stability: Stable under normal handling conditions.

Conditions to avoid: Not applicable for this product

Hazardous Combustion/Decomposition of Product: May emit toxic gases such as carbon dioxide, carbon monoxide and nitrogen oxide upon thermal decomposition.

5. HAZARDS IDENTIFICATION

Exposure may cause irritation to eyes, mucous membranes, upper respiratory tract and skin

6. TOXICOLOGICAL INFORMATION

To the best of our knowledge, the chemical, physical and toxicological properties have not been fully investigated.

RTECS No: Not assigned

Target Organs: Eyes; Respiratory system; Skin

Toxicity Data: No data available

7. REGULATORY INFORMATION

Classification: Caution: Substance not yet fully tested.

Safety Phrases: S24/25 - Avoid contact with skin and eyes
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
S28: After contact with skin, wash immediately with plenty of water
S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection

Risk Phrases:

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Wear appropriate chemical resistant gloves, safety goggles and other protective clothing to prevent contact with eyes and skin. Laboratory should be equipped with a safety shower and eye wash station. Avoid prolonged or repeated exposure. Do not breathe dust. Do not get in eyes, on skin or on clothing. Wash thoroughly after handling.

9. FIRST-AID MEASURES

In cases of SKIN CONTACT: Wash with copious amounts of water for at least 15 minutes. Remove contaminated clothing and shoes and wash before wearing. In case of eye contact, flush with copious amounts of water for at least 15 minutes.

In cases of INHALATION: Remove to fresh air and monitor breathing. If breathing becomes difficult, give oxygen. If breathing stops, give artificial respiration.

In cases of INGESTION: If swallowed, rinse mouth out with water, contact local poison centre and call a physician.

10. FIRE-FIGHTING MEASURES

Extinguishing Media: Material is non-combustible. Use extinguishing media appropriate to surrounding fire conditions.

Unusual Fire and Explosive Hazards: May emit toxic gases upon thermal decomposition.

Special Fire-Fighting Procedures: Wear protective clothing to prevent contact with skin and eyes.

11. ACCIDENTAL RELEASE MEASURES

Wear appropriate protective clothing. Cover spillage with suitable absorbent material. Using non-spark tools, sweep up material and place in an appropriate container. Decontaminate spill site with 10% caustic solution and ventilate area until after disposal is complete. Hold all material for appropriate disposal as described under DISPOSAL CONDITIONS.

12. ECOLOGICAL INFORMATION

Data not yet available - treat as potentially toxic if released into the environment.

13. DISPOSAL CONDITIONS

As specific country, federal, state and local environmental regulations are varied and change frequently, we recommend that you contact your local department for Health Services for information on the correct disposal of this product.

14. TRANSPORT INFORMATION

U.N.Number:
Proper Shipping Name:
IATA Class:
IATA Packing Group:

15. OTHER INFORMATION

Due to the nature of this material. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorised facilities. The above information is believed to be correct but does not purport to be all inclusive and should be used as a guide only for experienced personnel. Always consult your safety advisor and follow appropriate local and national safety legislature. The absence of warning must not, under any circumstance, be taken to mean that no hazard exists.

CAUTION — Not fully tested. For research use only. Not for human or veterinary use.

Product Information

Axitinib

Cat. No: 4350

Batch No: 1

N-Methyl-[[3[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide

Description: Potent inhibitor of VEGFR-1, -2 and -3 (IC₅₀ values are 0.2, 0.1 to 0.3, and 1.2 nM for VEGFR-2, VEGFR-3 and VEGFR-1 respectively). Inhibits angiogenesis and vascular permeability. Displays little activity at 'off-target' protein kinases and exhibits no significant activity in a broad protein kinase screen. Orally available.

Physical and Chemical Properties:


Batch Molecular Formula: C₂₂H₁₈N₄OS

Batch Molecular Weight: 386.47

CAS Number: [319460-85-0]

Physical Appearance: White solid

Batch Molecular Structure:



Solubility & Usage Info:

Soluble to 25 mM in DMSO

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20° C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Storage: Store at +4°C

References:

Hu-Lowe *et al* (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2 and 3. Clin.Cancer Res. **14** 7272. PMID:19010843

Ma and Waxman (2008) Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol.Cancer Ther. **7** 79. PMID:18202011



Congratulations on your purchase of Axitinib, sold under license from Pfizer, Inc. If your research with Axitinib results in a new discovery (e.g., new uses, new combinations, etc.) Pfizer is interested in discussing these discoveries with you. Also note that Pfizer has a Compound Transfer Program that provides a free sample of any Pfizer product at www.pfizer.com/research/rd_works/compound_transfer_program.jsp

CAUTION — Not fully tested. For research use only. Not for human or veterinary use.